Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Knobler

Showing results (601-610 of 640) with videos related to

Pageof 64
Sort By:
BMC Public Health|May 26, 2020
Substantial and sustained reduction in under-5 mortality, diarrhea, and pneumonia in Oshikhandass, Pakistan: evidence from two longitudinal cohort studies 15 years apartC L Hansen, B J J McCormick, S I Azam, et al.
Blood|June 2, 2007
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise Olsen, Eric Vonderheid, Nicola Pimpinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2025
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"Rudolf Stadler, Gabriele Roccuzzo, Pablo Ortiz-Romero, et al.
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.
Vaccine|December 22, 2016
Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort studyChristel Hoest, Jessica C Seidman, Gwenyth Lee, et al.
American Journal of Human Genetics|October 29, 2002
A highly significant association between a COMT haplotype and schizophreniaSagiv Shifman, Michal Bronstein, Meira Sternfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaE Olsen, M Duvic, A Frankel, et al.
Bone Marrow Transplantation|November 18, 2025
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxisAmandeep Salhotra, Dongyun Yang, Monzr M Al Malki, et al.
Pageof 64

Showing results (601-610 of 640) with videos related to

Sort By:
Pageof 64
BMC Public Health|May 26, 2020
Substantial and sustained reduction in under-5 mortality, diarrhea, and pneumonia in Oshikhandass, Pakistan: evidence from two longitudinal cohort studies 15 years apartC L Hansen, B J J McCormick, S I Azam, et al.
Blood|June 2, 2007
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise Olsen, Eric Vonderheid, Nicola Pimpinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2025
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"Rudolf Stadler, Gabriele Roccuzzo, Pablo Ortiz-Romero, et al.
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.
Vaccine|December 22, 2016
Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort studyChristel Hoest, Jessica C Seidman, Gwenyth Lee, et al.
American Journal of Human Genetics|October 29, 2002
A highly significant association between a COMT haplotype and schizophreniaSagiv Shifman, Michal Bronstein, Meira Sternfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaE Olsen, M Duvic, A Frankel, et al.
Bone Marrow Transplantation|November 18, 2025
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxisAmandeep Salhotra, Dongyun Yang, Monzr M Al Malki, et al.
Pageof 64